{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T01:45:01Z","timestamp":1788659101902,"version":"build-2803163510"},"reference-count":303,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"National Research Development and Innovation Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.pharmthera.2023.108523","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T20:41:48Z","timestamp":1693428108000},"page":"108523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response"],"prefix":"10.1016","volume":"250","author":[{"given":"Gabriella","family":"Juhasz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Gecse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Baksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2023.108523_bb0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s10194-021-01285-9","article-title":"Identification of disease- and headache-specific mediators and pathways in migraine using blood transcriptomic and metabolomic analysis","volume":"22","author":"Acz\u00e9l","year":"2021","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0010","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1212\/WNL.98.18_supplement.3177","article-title":"Real-world effectiveness of ubrogepant for the acute treatment of migraine when used in combination with an anti-calcitonin gene\u2013related peptide monoclonal antibody preventive: results from the COURAGE study (P10-2.003)","volume":"98","author":"Adams","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0015","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.18553\/jmcp.2020.26.11.1456","article-title":"The effectiveness and value of novel acute treatments for migraine","volume":"26","author":"Agboola","year":"2020","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/head.14244","article-title":"Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine","volume":"62","author":"Ailani","year":"2022","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0025","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice","volume":"61","author":"Ailani","year":"2021","journal-title":"Headache"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2023.108523_bb0030","first-page":"139","article-title":"Effects of rimegepant 75 mg on monthly migraine days: A 52-week, open-label extension study","volume":"62","author":"Ailani","year":"2022","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0035","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa2035908","article-title":"Atogepant for the preventive treatment of migraine","volume":"385","author":"Ailani","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0040","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/head.13682","article-title":"Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial","volume":"60","author":"Ailani","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s10194-023-01539-8","article-title":"The sense of stopping migraine prophylaxis","volume":"24","author":"Al-Hassany","year":"2023","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0050","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1097\/j.pain.0000000000002238","article-title":"Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine","volume":"162","author":"Al-Karagholi","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0055","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1093\/brain\/awz199","article-title":"Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine","volume":"142","author":"Al-Karagholi","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/03331024211040467","article-title":"Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks","volume":"42","author":"Alpuente","year":"2021","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0065","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ana.26472","article-title":"Salivary CGRP and erenumab treatment response: towards precision medicine in migraine","volume":"92","author":"Alpuente","year":"2022","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0070","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1111\/ene.14828","article-title":"Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: a real-world evidence study","volume":"28","author":"Alpuente","year":"2021","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0075","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1007\/s00415-022-11226-4","article-title":"Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience","volume":"269","author":"Altamura","year":"2022","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0080","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1007\/s10072-022-06184-8","article-title":"Gepants - a long way to cure: a narrative review","volume":"43","author":"Altamura","year":"2022","journal-title":"Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","article-title":"The American Headache Society position statement on integrating new migraine treatments into clinical practice","volume":"59","author":"American Headache Society","year":"2019","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0090","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40211-018-0299-5","article-title":"Migraine headache and depression in adults: a systematic review and meta-analysis","volume":"33","author":"Amiri","year":"2019","journal-title":"Neuropsychiatr"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10194-010-0282-4","article-title":"Migraine and psychiatric comorbidity: a review of clinical findings","volume":"12","author":"Antonaci","year":"2011","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0100","first-page":"360","article-title":"Analysis of shared heritability in common disorders of the brain","author":"Anttila","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0105","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231161261","article-title":"\u201cWearing-off\u201d efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials","volume":"43","author":"Asawavichienjinda","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s10194-022-01464-2","article-title":"Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences","volume":"23","author":"Ashina","year":"2022","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0115","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s10194-021-01279-7","article-title":"Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6months of treatment in the phase 3b FOCUS study","volume":"22","author":"Ashina","year":"2021","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0120","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/ene.14715","article-title":"Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial","volume":"28","author":"Ashina","year":"2021","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0125","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrneurol.2017.137","article-title":"Human models of migraine - short-term pain for long-term gain","volume":"13","author":"Ashina","year":"2017","journal-title":"Nature Reviews. Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0130","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","article-title":"Migraine: epidemiology and systems of care","volume":"397","author":"Ashina","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/head.14439","article-title":"Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial","volume":"63","author":"Ashina","year":"2023","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0140","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","article-title":"Migraine: disease characterisation, biomarkers, and precision medicine","volume":"397","author":"Ashina","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40122-021-00240-5","article-title":"Structural and functional brain changes in migraine","volume":"10","author":"Ashina","year":"2021","journal-title":"Pain and therapy"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0150","series-title":"The role of circadian rhythm in migraine","author":"Baksa","year":"2023"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0155","first-page":"37","article-title":"Why are migraineurs more depressed? A review of the factors contributing to the comorbidity of migraine and depression","volume":"19","author":"Baksa","year":"2017","journal-title":"Neuropsychopharmacologia Hungarica"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0160","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clineuro.2015.02.017","article-title":"Migraine features in migraineurs with and without anxiety-depression symptoms: a hospital-based study","volume":"132","author":"Baldacci","year":"2015","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0165","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","article-title":"Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients","volume":"23","author":"Barbanti","year":"2022","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0170","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","article-title":"Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)","volume":"23","author":"Barbanti","year":"2022","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0175","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.77146","article-title":"Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI study","volume":"11","author":"Basedau","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0180","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1212\/WNL.0b013e3182a6cb32","article-title":"Migraine and structural changes in the brain: a systematic review and meta-analysis","volume":"81","author":"Bashir","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0185","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221137092","article-title":"Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks","volume":"43","author":"Begasse de Dhaem","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0190","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/head.13930","article-title":"Safety of rimegepant, an Oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine","volume":"60","author":"Berman","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0195","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1468-2982.2002.00364.x","article-title":"Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study","volume":"22","author":"Bigal","year":"2002","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0200","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1468-2982.1997.1704488.x","article-title":"A 40-year follow-up of school children with migraine","volume":"17","author":"Bille","year":"1997","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0205","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40263-023-00988-8","article-title":"Rimegepant: A review in the acute treatment and preventive treatment of migraine","volume":"37","author":"Blair","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0210","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","article-title":"Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxina: A retrospective chart review","volume":"10","author":"Blumenfeld","year":"2021","journal-title":"Pain and therapy"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0215","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/head.14089","article-title":"Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis","volume":"61","author":"Blumenfeld","year":"2021","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0220","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/WCO.0000000000000687","article-title":"Advance in genetics of migraine","volume":"32","author":"de Boer","year":"2019","journal-title":"Current Opinion in Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0225","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40261-021-01034-5","article-title":"Evaluation of the pharmacokinetic interaction and safety of atogepant co-administered with acetaminophen or naproxen in healthy participants: A randomized trial","volume":"41","author":"Boinpally","year":"2021","journal-title":"Clinical Drug Investigation"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0230","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neuron.2012.01.001","article-title":"Understanding migraine through the lens of maladaptive stress responses: A model disease of allostatic load","volume":"73","author":"Borsook","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0235","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1111\/head.13929","article-title":"The spectrum of response to erenumab in patients with episodic migraine and subgroup analysis of patients achieving \u226550%, \u226575%, and 100% response","volume":"60","author":"Broessner","year":"2020","journal-title":"Headache"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2023.108523_bb0240","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10072-015-2156-7","article-title":"Migraine attacks in the pharmacy: A gender subanalysis on treatment preferences","volume":"36","author":"Brusa","year":"2015","journal-title":"Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0245","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11940-019-0557-2","article-title":"Antidepressants for preventive treatment of migraine","volume":"21","author":"Burch","year":"2019","journal-title":"Current Treatment Options in Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0250","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of action of onabotulinumtoxina in chronic migraine: A narrative review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0255","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1523\/JNEUROSCI.0373-15.2015","article-title":"Migraine: Multiple processes, complex pathophysiology","volume":"35","author":"Burstein","year":"2015","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0260","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s10194-020-01177-4","article-title":"Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study","volume":"21","author":"Buse","year":"2020","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0265","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/head.12150","article-title":"Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: Results of the American Migraine Prevalence and Prevention (AMPP) Study","volume":"53","author":"Buse","year":"2013","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0270","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s00415-012-6725-x","article-title":"Psychiatric comorbidities of episodic and chronic migraine","volume":"260","author":"Buse","year":"2013","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0275","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.18553\/jmcp.2020.20100","article-title":"Burden of illness among people with migraine and \u2265 4 monthly headache days while using acute and\/or preventive prescription medications for migraine","volume":"26","author":"Buse","year":"2020","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0280","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1526-4610.2009.01523.x","article-title":"Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan","volume":"49","author":"Cady","year":"2009","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0285","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1192\/bjp.185.3.191","article-title":"Migraine: another headache for psychiatrists?","volume":"185","author":"Cahill","year":"2004","journal-title":"The British Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0290","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s10194-021-01281-z","article-title":"Comorbidities of primary headache disorders: A literature review with meta-analysis","volume":"22","author":"Caponnetto","year":"2021","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0295","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1468-2982.2009.01874.x","article-title":"Underdiagnosis and undertreatment of migraine in Italy: A survey of patients attending for the first time 10 headache centres","volume":"29","author":"Cevoli","year":"2009","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0300","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.1007\/s12035-022-02930-3","article-title":"Role of omics in migraine research and management: A narrative review","volume":"59","author":"Chaturvedi","year":"2022","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0305","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/head.14062","article-title":"Real-world efficacy, tolerability, and safety of ubrogepant","volume":"61","author":"Chiang","year":"2021","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0310","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2147\/JPR.S244249","article-title":"Ubrogepant in the acute management of migraine: A narrative review","volume":"14","author":"Chiang","year":"2021","journal-title":"Journal of Pain Research"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0315","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s42003-021-02356-y","article-title":"New and sex-specific migraine susceptibility loci identified from a multiethnic genome-wide meta-analysis","volume":"4","author":"Choquet","year":"2021","journal-title":"Communications Biology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0320","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s10194-018-0927-2","article-title":"Migraine induction with calcitonin gene-related peptide in patients from erenumab trials","volume":"19","author":"Christensen","year":"2018","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0325","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s10194-020-01132-3","article-title":"Lasmiditan mechanism of action - Review of a selective 5-HT(1F) agonist","volume":"21","author":"Clemow","year":"2020","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0330","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/pm\/pnab093","article-title":"Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to onabotulinumtoxina in patients with chronic migraine","volume":"22","author":"Cohen","year":"2021","journal-title":"Pain Medicine"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0335","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/neurolint15010017","article-title":"Migraine disability improvement during treatment with galcanezumab in patients with chronic and high frequency episodic migraine","volume":"15","author":"di Cola","year":"2023","journal-title":"Neurology International"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0340","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"Croop","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0345","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0350","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1007\/s10072-022-06265-8","article-title":"Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients","volume":"43","author":"Curone","year":"2022","journal-title":"Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1680","article-title":"Genetic variants related to successful migraine prophylaxis with verapamil","volume":"9","author":"Cutrer","year":"2021","journal-title":"Molecular Genetics & Genomic Medicine"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0360","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11940-019-0556-3","article-title":"Beta-blockers for migraine prevention: A review article","volume":"21","author":"Danesh","year":"2019","journal-title":"Current Treatment Options in Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0365","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1007\/s10072-020-05022-z","article-title":"Early outcomes of migraine after erenumab discontinuation: data from a real-life setting","volume":"42","author":"De Matteis","year":"2021","journal-title":"Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0370","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/lary.24592","article-title":"The impact of comorbid migraine on quality-of-life outcomes after endoscopic sinus surgery","volume":"124","author":"DeConde","year":"2014","journal-title":"Laryngoscope"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0375","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-021-01644-5","article-title":"Atogepant: First approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0380","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/s12883-021-02451-x","article-title":"The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: A systematic literature review","volume":"21","author":"Deighton","year":"2021","journal-title":"BMC Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0385","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0390","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1526-4610.2006.00631.x","article-title":"Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention study","volume":"47","author":"Diamond","year":"2007","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0395","article-title":"Regular practice of autogenic training reduces migraine frequency and is associated with brain activity changes in response to fearful visual stimuli","volume":"15","author":"Dobos","year":"2021","journal-title":"Frontiers in Behavioral Neuroscience"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0400","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/0333102420966658","article-title":"Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine","volume":"41","author":"Dodick","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0405","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1526-4610.2007.00868.x","article-title":"Predictors of migraine headache recurrence: A pooled analysis from the eletriptan database","volume":"48","author":"Dodick","year":"2008","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0410","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1177\/0333102421989601","article-title":"Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis","volume":"41","author":"Drellia","year":"2021","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0415","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s10194-022-01411-1","article-title":"Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: Results from a retrospective chart study","volume":"23","author":"Driessen","year":"2022","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0420","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1212\/WNL.0000000000000866","article-title":"How transparent are migraine clinical trials? Repository of Registered Migraine Trials (RReMiT)","volume":"83","author":"Dufka","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0425","doi-asserted-by":"crossref","first-page":"1012831","DOI":"10.3389\/fpain.2022.1012831","article-title":"The value of brain MRI functional connectivity data in a machine learning classifier for distinguishing migraine from persistent post-traumatic headache","volume":"3","author":"Dumkrieger","year":"2022","journal-title":"Frontiers in Pain Research"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0430","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s10194-018-0852-4","article-title":"PACAP and its role in primary headaches","volume":"19","author":"Edvinsson","year":"2018","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0435","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","article-title":"Diagnosis and management of migraine in ten steps","volume":"17","author":"Eigenbrodt","year":"2021","journal-title":"Nature Reviews. Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0440","first-page":"62","article-title":"Mind-body therapies: Are the trial data getting stronger?","volume":"13","author":"Ernst","year":"2007","journal-title":"Alternative Therapies in Health and Medicine"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0445","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1093\/brain\/awac040","article-title":"The PACAP pathway is independent of CGRP in mouse models of migraine: Possible new drug target?","volume":"145","author":"Ernstsen","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259502","article-title":"Prevalence of migraine in adults with celiac disease: A case control cross-sectional study","volume":"16","author":"Fanaeian","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0455","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","article-title":"Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials","volume":"22","author":"Ferrari","year":"2002","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0460","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","article-title":"Oral triptans (serotonin 5-HT1B\/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials","volume":"358","author":"Ferrari","year":"2001","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0465","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1080\/13696998.2020.1814790","article-title":"Economic burden and risk factors of migraine disease progression in the US: a retrospective analysis of a commercial payer database","volume":"23","author":"Foster","year":"2020","journal-title":"Journal of Medical Economics"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0470","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10072-014-1750-4","article-title":"Gender and triptan efficacy: a pooled analysis of three double-blind, randomized, crossover, multicenter, Italian studies comparing frovatriptan vs. other triptans","volume":"35 Suppl 1","author":"Franconi","year":"2014","journal-title":"Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0475","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1177\/03331024211018137","article-title":"CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis","volume":"41","author":"Frank","year":"2021","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0480","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00228-016-2028-y","article-title":"Utilisation of prescription and over-the-counter triptans: A cross-sectional study in Stockholm, Sweden","volume":"72","author":"Frisk","year":"2016","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0485","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221145916","article-title":"The impact of epigenetic mechanisms in migraine: Current knowledge and future directions","volume":"43","author":"Gallardo","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0490","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8070928","article-title":"Hsa-miR-34a-5p and hsa-miR-375 as biomarkers for monitoring the effects of drug treatment for migraine pain in children and adolescents: A pilot study","volume":"8","author":"Gallelli","year":"2019","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0495","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/03331024211014616","article-title":"Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study","volume":"41","author":"Gantenbein","year":"2021","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0500","doi-asserted-by":"crossref","DOI":"10.3389\/fpain.2021.767162","article-title":"Sex differences of periaqueductal grey matter functional connectivity in migraine","volume":"2","author":"Gecse","year":"2021","journal-title":"Frontiers in Pain Research"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0505","first-page":"11","article-title":"Citalopram neuroendocrine challenge shows altered tryptophan and kynurenine metabolism in migraine","author":"Gecse","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0510","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/ana.26072","article-title":"Amylin analog pramlintide induces migraine-like attacks in patients","volume":"89","author":"Ghanizada","year":"2021","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0515","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ana.410230214","article-title":"Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system","volume":"23","author":"Goadsby","year":"1988","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0520","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: A disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0525","doi-asserted-by":"crossref","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","article-title":"Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study","volume":"95","author":"Goadsby","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0530","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3598","article-title":"Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine","volume":"48","author":"Gormley","year":"2016","journal-title":"Nature Genetics"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0535","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1526-4610.2002.02123.x","article-title":"Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: Outcome at 3 years","volume":"42","author":"Grazzi","year":"2002","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0540","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41582-019-0255-4","article-title":"The metabolic face of migraine \u2014 from pathophysiology to treatment","volume":"15","author":"Gross","year":"2019","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0545","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/0333102416639512","article-title":"Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine","volume":"37","author":"Guo","year":"2017","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0550","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s10194-022-01523-8","article-title":"PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine","volume":"23","author":"Guo","year":"2022","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105946","article-title":"Role of PACAP in migraine: An alternative to CGRP?","volume":"176","author":"Guo","year":"2023","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0560","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231159366","article-title":"Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials","volume":"43","author":"Haghdoost","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0565","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s10194-019-1046-4","article-title":"Differences in treatment response between migraine with aura and migraine without aura: Lessons from clinical practice and RCTs","volume":"20","author":"Hansen","year":"2019","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0570","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1212\/WNL.0000000000001535","article-title":"Reduced efficacy of sumatriptan in migraine with aura vs without aura","volume":"84","author":"Hansen","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0575","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221145962","article-title":"Migraine genetics: Status and road forward","volume":"43","author":"Harder","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0580","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s10194-021-01357-w","article-title":"Metabolic profile changes in serum of migraine patients detected using 1H-NMR spectroscopy","volume":"22","author":"Harder","year":"2021","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0585","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41588-021-00990-0","article-title":"Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles","volume":"54","author":"Hautakangas","year":"2022","journal-title":"Nature Genetics"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0590","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1526-4610.2007.00990.x","article-title":"Direct cost burden among insured US employees with migraine","volume":"48","author":"Hawkins","year":"2008","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0595","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/JOM.0b013e31803b9510","article-title":"Indirect cost burden of migraine in the United States","volume":"49","author":"Hawkins","year":"2007","journal-title":"Journal of Occupational and Environmental Medicine"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0600","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","article-title":"Systematic review of migraine prophylaxis adherence and persistence","volume":"20","author":"Hepp","year":"2014","journal-title":"Journal of Managed Care Pharmacy"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0605","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/0333102414547138","article-title":"Adherence to oral migraine-preventive medications among patients with chronic migraine","volume":"35","author":"Hepp","year":"2015","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0610","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention","volume":"83","author":"Ho","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0615","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s13311-018-0616-5","article-title":"Glutamate and its receptors as therapeutic targets for migraine","volume":"15","author":"Hoffmann","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0620","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c4871","article-title":"Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: Randomised controlled trial","volume":"341","author":"Holroyd","year":"2010","journal-title":"Bmj"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0625","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1526-4610.1995.hed3502070.x","article-title":"Migraine and concomitant symptoms among 8167 adult twin pairs","volume":"35","author":"Honkasalo","year":"1995","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.136380","article-title":"The role of TRP ion channels in migraine and headache","volume":"768","author":"Iannone","year":"2022","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0635","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/ene.15260","article-title":"Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine","volume":"29","author":"Iannone","year":"2022","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache classification committee of the international headache society (IHS) The International Classification of Headache Disorders","volume":"38","author":"International Headache Society","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0645","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/ene.14431","article-title":"Estimating the savings associated with a migraine-free life: Results from the Spanish Atlas","volume":"27","author":"Irimia","year":"2020","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0650","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0333102420977106","article-title":"Interictal amylin levels in chronic migraine patients: A case-control study","volume":"41","author":"Irimia","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0655","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212785","article-title":"Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis","volume":"14","author":"Jackson","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0660","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s10194-021-01378-5","article-title":"Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201)","volume":"23","author":"Johnston","year":"2022","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0665","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14737167.2021.1945444","article-title":"Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis","volume":"22","author":"Johnston","year":"2022","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0670","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/AJP.0000000000001072","article-title":"Rimegepant, ubrogepant, and lasmiditan in the acute treatment of migraine examining the benefit-risk profile using number needed to treat\/harm","volume":"38","author":"Johnston","year":"2022","journal-title":"The Clinical Journal of Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0675","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1526-4610.2006.00718.x","article-title":"Effects of autogenic training on nitroglycerin-induced headaches","volume":"47","author":"Juhasz","year":"2007","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0680","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1468-2982.2005.00836.x","article-title":"Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack","volume":"25","author":"Juhasz","year":"2005","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0685","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pain.2003.09.008","article-title":"NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release","volume":"106","author":"Juhasz","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0690","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.741135","article-title":"Association between asthma and migraine: A systematic review and meta-analysis of observational studies","volume":"2","author":"Kang","year":"2021","journal-title":"Frontiers in Allergy"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0695","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2648.2006.03779.x","article-title":"Autogenic training to reduce anxiety in nursing students: randomized controlled trial","volume":"53","author":"Kanji","year":"2006","journal-title":"Journal of Advanced Nursing"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0700","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s40263-022-00948-8","article-title":"New oral drugs for migraine","volume":"36","author":"Karsan","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0705","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s10194-018-0839-1","article-title":"Poor medical care for people with migraine in Europe - evidence from the Eurolight study","volume":"19","author":"Katsarava","year":"2018","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0710","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/0333102412459478","article-title":"Neglected headache: Ignorance, arrogance or insouciance?","volume":"32","author":"Katsarava","year":"2012","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0715","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1468-2982.2007.01303.x","article-title":"The triggers or precipitants of the acute migraine attack","volume":"27","author":"Kelman","year":"2007","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0720","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archpsyc.63.10.1113","article-title":"Personality and major depression: a Swedish longitudinal, population-based twin study","volume":"63","author":"Kendler","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0725","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1177\/0333102419840780","article-title":"A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody","volume":"39","author":"Kielbasa","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0730","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-065787","article-title":"Comorbidities in patients with migraine in Japan: A cross-sectional study using data from National Health and Wellness Survey","volume":"12","author":"Kikui","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0735","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221128250","article-title":"Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial","volume":"43","author":"Klein","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0740","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11916-019-0742-8","article-title":"Episodic migraine comorbidities: Avoiding pitfalls and taking therapeutic opportunities","volume":"23","author":"Klenofsky","year":"2019","journal-title":"Current Pain and Headache Reports"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0745","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/s41598-019-41867-x","article-title":"Altered neural activity to monetary reward\/loss processing in episodic migraine","volume":"9","author":"Kocsel","year":"2019","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0750","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000364","article-title":"Migraine polygenic risk score associates with efficacy of migraine-specific drugs","volume":"5","author":"Kogelman","year":"2019","journal-title":"Neurology Genetics"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0755","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261570","article-title":"Inter-individual differences in pain anticipation and pain perception in migraine: Neural correlates of migraine frequency and cortisol-to-dehydroepiandrosterone sulfate (DHEA-S) ratio","volume":"16","author":"K\u00f6k\u00f6nyei","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0760","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1080\/08870446.2016.1235166","article-title":"Rumination in migraine: Mediating effects of brooding and reflection between migraine and psychological distress","volume":"31","author":"Kokonyei","year":"2016","journal-title":"Psychology & Health"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0765","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jns.2016.08.008","article-title":"Biomarkers of migraine: Part 1 - genetic markers","volume":"369","author":"Kondratieva","year":"2016","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0770","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s40122-022-00388-8","article-title":"Lasmiditan for patients with migraine and contraindications to triptans: A post hoc analysis","volume":"11","author":"Krege","year":"2022","journal-title":"Pain and therapy"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0775","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0333102419855080","article-title":"Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN","volume":"39","author":"Krege","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0780","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1523\/JNEUROSCI.1796-21.2022","article-title":"Three dimensions of association link migraine symptoms and functional connectivity","volume":"42","author":"Krimmel","year":"2022","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0785","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","article-title":"Long-term safety and tolerability of eptinezumab in patients with chronic migraine: A 2-year, open-label, phase 3 trial","volume":"21","author":"Kudrow","year":"2021","journal-title":"BMC Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0790","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1212\/01.WNL.0000154528.21485.3A","article-title":"Migraine, headache, and the risk of stroke in women: a prospective study","volume":"64","author":"Kurth","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0795","doi-asserted-by":"crossref","DOI":"10.1177\/25158163221075596","article-title":"Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study","volume":"5","author":"L\u2019Italien","year":"2022","journal-title":"Cephalalgia Reports"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0800","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/j.pain.0000000000001801","article-title":"Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system","volume":"161","author":"Labastida-Ram\u00edrez","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0805","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40265-019-01225-7","article-title":"Lasmiditan: First approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0810","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","article-title":"The comparative effectiveness of migraine preventive drugs: A systematic review and network meta-analysis","volume":"24","author":"Lampl","year":"2023","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0815","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","article-title":"CGRP may play a causative role in migraine","volume":"22","author":"Lassen","year":"2002","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0820","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221146315","article-title":"New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy","volume":"43","author":"Lee","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0825","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1007\/s12325-020-01494-9","article-title":"Evaluation of patients with insufficient efficacy and\/or tolerability to triptans for the acute treatment of migraine: A systematic literature review","volume":"37","author":"Leroux","year":"2020","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0830","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.pain.2007.03.012","article-title":"Mast cell degranulation activates a pain pathway underlying migraine headache","volume":"130","author":"Levy","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0835","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1375\/twin.15.2.158","article-title":"Causes of comorbidity: pleiotropy or causality? Shared genetic and environmental influences on migraine and neuroticism","volume":"15","author":"Ligthart","year":"2012","journal-title":"Twin Research and Human Genetics"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0840","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00439-013-1370-8","article-title":"Genetic risk score analysis indicates migraine with and without comorbid depression are genetically different disorders","volume":"133","author":"Ligthart","year":"2014","journal-title":"Human Genetics"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0845","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1526-4610.2010.01705.x","article-title":"The shared genetics of migraine and anxious depression","volume":"50","author":"Ligthart","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0850","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","article-title":"The cost of headache disorders in Europe: the Eurolight project","volume":"19","author":"Linde","year":"2012","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0855","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221141686","article-title":"Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials","volume":"43","author":"Lipton","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0860","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/head.14097","article-title":"Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study","volume":"61","author":"Lipton","year":"2021","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0865","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","article-title":"Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: A phase 3, double-blind, randomised, placebo-controlled multicentre trial","volume":"22","author":"Lipton","year":"2023","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0870","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: The ACHIEVE II randomized clinical Trial","volume":"322","author":"Lipton","year":"2019","journal-title":"Jama"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0875","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/head.13342","article-title":"Identifying natural subgroups of migraine based on comorbidity and concomitant condition profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study","volume":"58","author":"Lipton","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0880","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/head.14259","article-title":"Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study","volume":"62","author":"Lipton","year":"2022","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0885","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1212\/WNL.0000000000201568","article-title":"Effect of atogepant for preventive migraine treatment on patient-reported outcomes in the randomized, double-blind, Phase 3 ADVANCE Trial","volume":"100","author":"Lipton","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0890","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1129-2377-14-47","article-title":"Health-care utilization for primary headache disorders in China: A population-based door-to-door survey","volume":"14","author":"Liu","year":"2013","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0895","article-title":"Calcitonin gene-related peptide monoclonal antibody versus botulinum toxin for the preventive treatment of chronic migraine: Evidence from indirect treatment comparison","volume":"12","author":"Lu","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0900","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1526-4610.2006.00430.x","article-title":"Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey","volume":"46","author":"Lucas","year":"2006","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0905","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/01.CIR.98.1.25","article-title":"Coronary side-effect potential of current and prospective antimigraine drugs","volume":"98","author":"MaassenVanDenBrink","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0910","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1212\/WNL.0000000000001606","article-title":"Shared genetic basis for migraine and ischemic stroke: A genome-wide analysis of common variants","volume":"84","author":"Malik","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0915","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-244X-8-41","article-title":"Relaxation training for anxiety: a ten-years systematic review with meta-analysis","volume":"8","author":"Manzoni","year":"2008","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0920","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s10194-019-1009-9","article-title":"Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)","volume":"20","author":"Martelletti","year":"2019","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0925","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.brat.2015.07.005","article-title":"Cognitive behavior therapy for comorbid migraine and\/or tension-type headache and major depressive disorder: An exploratory randomized controlled trial","volume":"73","author":"Martin","year":"2015","journal-title":"Behaviour Research and Therapy"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0930","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brat.2014.07.002","article-title":"Behavioral management of the triggers of recurrent headache: A randomized controlled trial","volume":"61","author":"Martin","year":"2014","journal-title":"Behaviour Research and Therapy"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0935","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s10194-022-01438-4","article-title":"Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: A pooled analysis of phase 3 studies","volume":"23","author":"McAllister","year":"2022","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0940","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1177\/03331024221089567","article-title":"Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine","volume":"42","author":"McAllister","year":"2022","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0945","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0022-3956(93)90008-P","article-title":"Headache syndromes and psychiatric disorders: Association and familial transmission","volume":"27","author":"Merikangas","year":"1993","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0950","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fneur.2020.00221","article-title":"What we gain from machine learning studies in headache patients","volume":"11","author":"Messina","year":"2020","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0955","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231152169","article-title":"Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis","volume":"43","author":"Messina","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0960","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/jnnp-2015-312233","article-title":"Migraine and its psychiatric comorbidities","volume":"87","author":"Minen","year":"2016","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0965","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s10194-017-0813-3","article-title":"Patients\u2019 preferences for headache acute and preventive treatment","volume":"18","author":"Mitsikostas","year":"2017","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0970","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s10194-020-01204-4","article-title":"Neuromodulation techniques for acute and preventive migraine treatment: A systematic review and meta-analysis of randomized controlled trials","volume":"21","author":"Moisset","year":"2020","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0975","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11061656","article-title":"New generation gepants: Migraine acute and preventive medications","volume":"11","author":"Moreno-Ajona","year":"2022","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0980","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/hbm.24854","article-title":"Neuroimaging features of whole-brain functional connectivity predict attack frequency of migraine","volume":"41","author":"Mu","year":"2020","journal-title":"Human Brain Mapping"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0985","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1375\/136905203770326420","article-title":"Genetic and environmental influences on migraine: a twin study across six countries","volume":"6","author":"Mulder","year":"2003","journal-title":"Twin Research"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0990","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s11916-022-01077-z","article-title":"Real-world patient experience of CGRP-targeting therapy for migraine: A narrative review","volume":"26","author":"Murray","year":"2022","journal-title":"Current Pain and Headache Reports"},{"key":"10.1016\/j.pharmthera.2023.108523_bb0995","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00002018-200326020-00003","article-title":"Tolerability of the triptans: Clinical implications","volume":"26","author":"Nappi","year":"2003","journal-title":"Drug Safety"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1000","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s10194-017-0816-0","article-title":"Headache and pregnancy: A systematic review","volume":"18","author":"Negro","year":"2017","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1005","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1007\/s00415-021-10930-x","article-title":"Myocardial infarction, stroke and cardiovascular mortality among migraine patients: A systematic review and meta-analysis","volume":"269","author":"Ng","year":"2022","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1010","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020569","article-title":"Novel therapeutic targets for migraine","volume":"11","author":"Nisar","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1015","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11154359","article-title":"Reducing the burden of migraine: Safety and efficacy of CGRP pathway-targeted preventive treatments","volume":"11","author":"Nissan","year":"2022","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1020","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2662","article-title":"Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies","volume":"12","author":"Nsaka","year":"2022","journal-title":"Brain and Behavior: A Cognitive Neuroscience Perspective"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1025","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1038\/s41598-022-12545-2","article-title":"Low adherence to the guideline for the acute treatment of migraine","volume":"12","author":"Olesen","year":"2022","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1030","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine","volume":"350","author":"Olesen","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1035","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/ana.410280610","article-title":"Timing and topography of cerebral blood flow, aura, and headache during migraine attacks","volume":"28","author":"Olesen","year":"1990","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108523_bb1040","article-title":"Choosing the Right Triptan","volume":"3","author":"Oliver","year":"2003","journal-title":"Practical Pain Management"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1045","doi-asserted-by":"crossref","first-page":"e1899","DOI":"10.1212\/WNL.0000000000007313","article-title":"Large-scale plasma metabolome analysis reveals alterations in HDL metabolism in migraine","volume":"92","author":"Onderwater","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1050","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/head.13210","article-title":"The economic cost of patients with migraine headache referred to specialist clinics","volume":"58","author":"Osumili","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/03331024211048765","article-title":"Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study","volume":"42","author":"Overeem","year":"2022","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1060","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s40263-021-00834-9","article-title":"Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: A systematic review with meta-analysis","volume":"35","author":"Overeem","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1065","doi-asserted-by":"crossref","DOI":"10.3390\/cells12010143","article-title":"Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: A systematic review of real-world data","volume":"12","author":"Pavelic","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261477","article-title":"A replication study separates polymorphisms behind migraine with and without depression","volume":"16","author":"Petschner","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1075","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s10194-019-1027-7","article-title":"A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years","volume":"20","author":"Piccinni","year":"2019","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1080","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s10194-022-01440-w","article-title":"Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: Network meta-analysis findings","volume":"23","author":"Polavieja","year":"2022","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1085","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/head.14128","article-title":"Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine","volume":"61","author":"Popoff","year":"2021","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1090","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s12325-022-02369-x","article-title":"Health state utility mapping of rimegepant for the preventive treatment of migraine: Double-blind treatment phase and open label extension (BHV3000-305)","volume":"40","author":"Powell","year":"2023","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1095","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/03007995.2022.2059975","article-title":"Long-term treatment with galcanezumab in patients with chronic migraine: Results from the open-label extension of the REGAIN study","volume":"38","author":"Pozo-Rosich","year":"2022","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1100","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s13311-018-0614-7","article-title":"Targeted nitric oxide synthase inhibitors for migraine","volume":"15","author":"Pradhan","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1105","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231151419","article-title":"Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature","volume":"43","author":"Puledda","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1110","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1177\/0333102412454945","article-title":"Low rate of self-awareness and medical recognition of migraine in Germany","volume":"32","author":"Radtke","year":"2012","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1115","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221137091","article-title":"Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review","volume":"43","author":"Raffaelli","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1120","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15010293","article-title":"Change of CGRP plasma concentrations in migraine after discontinuation of CGRP-(Receptor) monoclonal antibodies","volume":"15","author":"Raffaelli","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s10194-022-01417-9","article-title":"Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: A real-world experience","volume":"23","author":"Raffaelli","year":"2022","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1130","doi-asserted-by":"crossref","first-page":"fcac311","DOI":"10.1093\/braincomms\/fcac311","article-title":"Headache classification and automatic biomarker extraction from structural MRIs using deep learning","volume":"5","author":"Rahman Siddiquee","year":"2023","journal-title":"Brain Communications"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1135","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1093\/brain\/awaa242","article-title":"Functional gene networks reveal distinct mechanisms segregating in migraine families","volume":"143","author":"Rasmussen","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1140","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1474-4422(04)00855-5","article-title":"Barriers to headache care in India and efforts to improve the situation","volume":"3","author":"Ravishankar","year":"2004","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1145","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/03331024211053571","article-title":"Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial","volume":"42","author":"Reuter","year":"2022","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/03331024211048507","article-title":"Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study","volume":"42","author":"Reuter","year":"2022","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1155","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3390\/brainsci12121612","article-title":"Gepants for acute and preventive migraine treatment: a narrative review","volume":"12","author":"Rissardo","year":"2022","journal-title":"Brain Sciences"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1160","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/head.13951","article-title":"Real-world patient experience with erenumab for the preventive treatment of migraine","volume":"60","author":"Robblee","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1165","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1054\/jpai.2001.24551","article-title":"Gender role expectations of pain: Relationship to sex differences in pain","volume":"2","author":"Robinson","year":"2001","journal-title":"The Journal of Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1170","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1212\/WNL.0000000000008956","article-title":"Are machine learning approaches the future to study patients with migraine?","volume":"94","author":"Rocca","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11916-020-00865-9","article-title":"Fear, avoidance, and disability in headache disorders","volume":"24","author":"Rogers","year":"2020","journal-title":"Current Pain and Headache Reports"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1180","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/head.13427","article-title":"100% response rate to galcanezumab in patients with episodic migraine: A post hoc analysis of the results from phase 3, randomized, double-blind, placebo-controlled EVOLVE-1 and EVOLVE-2 studies","volume":"58","author":"Rosen","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1185","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/head.13653","article-title":"FORWARD study: Evaluating the comparative effectiveness of onabotulinumtoxina and topiramate for headache prevention in adults with chronic migraine","volume":"59","author":"Rothrock","year":"2019","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynpai.2022.100089","article-title":"Analysis of the DNA methylation pattern of the promoter region of calcitonin gene-related peptide 1 gene in patients with episodic migraine: An exploratory case-control study","volume":"11","author":"Rubino","year":"2022","journal-title":"Neurobiology of Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1195","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","article-title":"Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?","volume":"186","author":"Rubio-Beltr\u00e1n","year":"2018","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1200","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221143538","article-title":"Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review","volume":"43","author":"Ruiz","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1205","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1468-2982.1996.1605305.x","article-title":"Migraine without aura and migraine with aura are inherited disorders","volume":"16","author":"Russell","year":"1996","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1215","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s10194-022-01502-z","article-title":"European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure","volume":"23","author":"Sacco","year":"2022","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1220","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","article-title":"Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019","volume":"163","author":"Safiri","year":"2022","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1225","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11033-021-06799-8","article-title":"Is there any association between migraine headache and polycystic ovary syndrome (PCOS)? A review article","volume":"49","author":"Sarahian","year":"2022","journal-title":"Molecular Biology Reports"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1230","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/j.1526-4610.2009.01486.x","article-title":"The stress and migraine interaction","volume":"49","author":"Sauro","year":"2009","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1235","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221128278","article-title":"Functional magnetic resonance imaging in migraine: A systematic review","volume":"43","author":"Schramm","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1240","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/brain\/aww097","article-title":"The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks","volume":"139","author":"Schulte","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1245","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ana.25697","article-title":"Longitudinal neuroimaging over 30Days: Temporal characteristics of migraine","volume":"87","author":"Schulte","year":"2020","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1250","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1177\/0333102420951465","article-title":"The migraineur\u2019s brain networks: Continuous resting state fMRI over 30 days","volume":"40","author":"Schulte","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1255","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1526-4610.2009.01425.x","article-title":"A twin study of depression and migraine: Evidence for a shared genetic vulnerability","volume":"49","author":"Schur","year":"2009","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1260","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1474-4422(14)70193-0","article-title":"Functional MRI of migraine","volume":"14","author":"Schwedt","year":"2015","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1265","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/head.12584","article-title":"Accurate classification of chronic migraine via brain magnetic resonance imaging","volume":"55","author":"Schwedt","year":"2015","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/03331024211042385","article-title":"Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial","volume":"42","author":"Schwedt","year":"2022","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1275","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s10194-022-01526-5","article-title":"Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab","volume":"23","author":"Schwedt","year":"2022","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1280","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/WCO.0b013e328337b884","article-title":"What have we learnt from triggering migraine?","volume":"23","author":"Schytz","year":"2010","journal-title":"Current Opinion in Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1285","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40265-020-01301-3","article-title":"Rimegepant: First Approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1290","doi-asserted-by":"crossref","first-page":"1130239","DOI":"10.3389\/fpain.2023.1130239","article-title":"Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review","volume":"4","author":"Shah","year":"2023","journal-title":"Frontiers in Pain Research"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1295","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1177\/0333102409354390","article-title":"Quantifying the return of headache in triptan-treated migraineurs: an observational study","volume":"30","author":"Sheftell","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1300","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","article-title":"The impact of fremanezumab on medication overuse in patients with chronic migraine: Subgroup analysis of the HALO CM study","volume":"21","author":"Silberstein","year":"2020","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1305","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12325-022-02346-4","article-title":"Adverse events reported with therapies targeting the CGRP pathway during the First 6 months post-launch: A retrospective analysis using the FDA adverse events reporting system","volume":"40","author":"Silberstein","year":"2023","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1310","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s10194-022-01436-6","article-title":"Galcanezumab effect on \"whole pain burden\" and multidimensional outcomes in migraine patients with previous unsuccessful treatments: A real-world experience","volume":"23","author":"Silvestro","year":"2022","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1315","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.656294","article-title":"Additive interaction between onabotulinumtoxin-A and erenumab in patients with refractory migraine","volume":"12","author":"Silvestro","year":"2021","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1320","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1111\/head.13970","article-title":"Efficacy of galcanezumab for migraine prevention in patients with a medical history of anxiety and\/or depression: A post hoc analysis of the phase 3, randomized, double-blind, placebo-controlled REGAIN, and pooled EVOLVE-1 and EVOLVE-2 studies","volume":"60","author":"Smitherman","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1325","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/01.WNL.0000158326.31368.04","article-title":"Headache, cerebrovascular symptoms, and stroke: The atherosclerosis risk in communities study","volume":"64","author":"Stang","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1330","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s10194-019-0985-0","article-title":"Primary headaches during lifespan","volume":"20","author":"Straube","year":"2019","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1335","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s13311-017-0602-3","article-title":"Targeted orexin and hypothalamic neuropeptides for migraine","volume":"15","author":"Strother","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1340","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s10194-019-1017-9","article-title":"Advances in genetics of migraine","volume":"20","author":"Sutherland","year":"2019","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1345","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-002057","article-title":"The contribution of stress to the comorbidity of migraine and major depression: Results from a prospective cohort study","volume":"3","author":"Swanson","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1350","article-title":"Association between migraine frequency and neural response to emotional faces: An fMRI study","volume":"22","author":"Szab\u00f3","year":"2019","journal-title":"NeuroImage: Clinical"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1355","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.ajhg.2021.09.011","article-title":"Genetic overlap and causality between blood metabolites and migraine","volume":"108","author":"Tanha","year":"2021","journal-title":"American Journal of Human Genetics"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1360","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/head.13791","article-title":"Gepants","volume":"60","author":"Tepper","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1365","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial","volume":"92","author":"Tepper","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1370","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/archneur.59.7.1084","article-title":"Mechanisms of action of the 5-HT1B\/1D receptor agonists","volume":"59","author":"Tepper","year":"2002","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1375","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2022.148100","article-title":"Proteomics analysis revealed the presence of inflammatory and oxidative stress markers in the plasma of migraine patients during the pain period","volume":"1797","author":"Togha","year":"2022","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1380","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/WCO.0000000000000689","article-title":"How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective","volume":"32","author":"Torres-Ferrus","year":"2019","journal-title":"Current Opinion in Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1385","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40262-020-00966-z","article-title":"Pharmacokinetics, safety, and tolerability of lasmiditan in pediatric patients with migraine","volume":"60","author":"Tsai","year":"2021","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1390","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11940-017-0463-4","article-title":"Anti-CGRP monoclonal antibodies: The next era of migraine Prevention?","volume":"19","author":"Tso","year":"2017","journal-title":"Current Treatment Options in Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1395","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1177\/0333102413483931","article-title":"Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients","volume":"33","author":"Tuka","year":"2013","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1400","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s10194-021-01239-1","article-title":"Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period","volume":"22","author":"Tuka","year":"2021","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1405","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1001\/jama.2021.7939","article-title":"Acute treatments for episodic migraine in adults: A systematic review and meta-analysis","volume":"325","author":"VanderPluym","year":"2021","journal-title":"Jama"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1410","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2147\/PPA.S346660","article-title":"Treatment patterns for calcitonin gene-related peptide monoclonal antibodies including galcanezumab versus conventional preventive treatments for migraine: A retrospective US claims study","volume":"16","author":"Varnado","year":"2022","journal-title":"Patient Preference and Adherence"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1415","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2174\/1871527314666150429114040","article-title":"Drug targets of migraine and neuropathy: Treatment of hyperexcitability","volume":"14","author":"V\u00e9csei","year":"2015","journal-title":"CNS & Neurological Disorders Drug Targets"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1420","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nrd3793","article-title":"Kynurenines in the CNS: Recent advances and new questions","volume":"12","author":"V\u00e9csei","year":"2013","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1425","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","article-title":"Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: A multicenter prospective cohort study (the GARLIT study)","volume":"22","author":"Vernieri","year":"2021","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1430","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","article-title":"Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: An observational longitudinal cohort study","volume":"22","author":"Vernieri","year":"2021","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1435","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1474-4422(16)30293-9","article-title":"Sex differences in the epidemiology, clinical features, and pathophysiology of migraine","volume":"16","author":"Vetvik","year":"2017","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1440","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/ene.14098","article-title":"Poor patient awareness and frequent misdiagnosis of migraine: Findings from a large transcontinental cohort","volume":"27","author":"Viana","year":"2020","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1445","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/head.14305","article-title":"The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review","volume":"62","author":"Vig","year":"2022","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1450","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1468-2982.1996.1604264.x","article-title":"Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients","volume":"16","author":"Visser","year":"1996","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1455","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s10194-022-01483-z","article-title":"Serum CGRP in migraine patients using erenumab as preventive treatment","volume":"23","author":"de Vries Lentsch","year":"2022","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1460","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/acn3.302","article-title":"Metabotropic glutamate receptor 5: A target for migraine therapy","volume":"3","author":"Waung","year":"2016","journal-title":"Annals of Clinical Translational Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1465","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1177\/0333102420975395","article-title":"Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial","volume":"41","author":"Wienholtz","year":"2021","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1470","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000010","article-title":"Genetic analysis for a shared biological basis between migraine and coronary artery disease","volume":"1","author":"Winsvold","year":"2015","journal-title":"Neurology Genetics"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1475","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/toxsci\/kfac051","article-title":"Comparing the liver safety profiles of 4 next-generation CGRP receptor antagonists to the hepatotoxic CGRP inhibitor telcagepant using quantitative systems toxicology modeling","volume":"188","author":"Woodhead","year":"2022","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1480","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s10194-016-0703-0","article-title":"Network meta-analysis of migraine disorder treatment by NSAIDs and triptans","volume":"17","author":"Xu","year":"2016","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1485","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/0333102419883355","article-title":"Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies","volume":"40","author":"Xu","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1490","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28544","article-title":"Comparison of new pharmacologic agents with triptans for treatment of migraine: A systematic review and meta-analysis","volume":"4","author":"Yang","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1495","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1111\/jcmm.14390","article-title":"The exploration of mechanisms of comorbidity between migraine and depression","volume":"23","author":"Zhang","year":"2019","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1500","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1038\/ncomms5212","article-title":"Human symptoms-disease network","volume":"5","author":"Zhou","year":"2014","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1505","doi-asserted-by":"crossref","first-page":"e2794","DOI":"10.1212\/WNL.0000000000010740","article-title":"Central effects of erenumab in migraine patients: An event-related functional imaging study","volume":"95","author":"Ziegeler","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1510","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1526-4610.2003.03049.x","article-title":"Effect of autogenic training on drug consumption in patients with primary headache: An 8-month follow-up study","volume":"43","author":"Zsombok","year":"2003","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2023.108523_bb1515","first-page":"25","article-title":"Effect of autogenic training with cognitive and symbol therapy on the treatment of patients with primary headache","volume":"20","author":"Zsomb\u00f3k","year":"2005","journal-title":"Psychiatria Hungarica"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823001870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823001870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:37:07Z","timestamp":1759012627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725823001870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":303,"alternative-id":["S0163725823001870"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108523","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108523","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108523"}}